Ask AI

Advances in Oral Targeted Therapies for HR+/HER2- Breast Cancer: Best Practices for Oncology Pharmacists

Enhance your ability to integrate oral targeted therapies for HR-positive/HER2-negative breast cancer into clinical practice to individualize patient care and improve outcomes through certified downloadable slides, certified text modules, an expert-authored ClinicalThought commentary, and an audio podcast.

Share

Program Content

Activities

HRpos HER2neg Breast Cancer
Advances in Oral Targeted Therapies for HR+/HER2- Breast Cancer: Best Practices for Oncology Pharmacists
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 20, 2026

Expires: November 19, 2026

HR Positive Breast Cancer Targeted Therapy
Optimizing Oral Targeted Therapies in HR+/HER2- Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 28, 2026

Expires: January 27, 2027

Activities

Optimizing Oral Targeted Therapies in HRpos HER2neg Breast Cancer
Optimizing the Use of Targeted Therapies in Breast Cancer: Dosing, Toxicity Management, and Adherence
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: July 28, 2026

Expires: January 27, 2027

Oral Therapies in HR Positive HER2 Negative Breast Cancer
Targeted Therapy Advances in HR+/HER2- Breast Cancer: Best Practices for Oncology Pharmacists
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: July 31, 2026

Expires: January 30, 2027

Activities

Oral Therapy HRpos HER2neg BC
Q&A on Oral Targeted Therapies in HR+/HER2- Breast Cancer for Oncology Pharmacists
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 28, 2026

Provided by

ProCE Banner

Provided by ProCE, LLC.

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca